<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827735</url>
  </required_header>
  <id_info>
    <org_study_id>A092737</org_study_id>
    <secondary_id>ISRCTN27852285</secondary_id>
    <nct_id>NCT01827735</nct_id>
  </id_info>
  <brief_title>Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2</brief_title>
  <acronym>DILT1D</acronym>
  <official_title>Adaptive Study of IL-2 Dose on Regulatory T Cells in Type 1 Diabetes (DILT1D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 diabetes is the most common severe chronic autoimmune disease worldwide and is caused&#xD;
      by the autoimmune (loss of self tolerance) mediated destruction of the insulin producing&#xD;
      pancreatic beta cells thus leading to insulin deficiency and development of hyperglycaemia.&#xD;
      Currently, medical management of type 1 diabetes focuses on intensive insulin replacement&#xD;
      therapy to limit complications (retinopathy, nephropathy, neuropathy); nevertheless clinical&#xD;
      outcomes remain sub optimal. There are intensive efforts to design novel immunotherapies that&#xD;
      can arrest the autoimmune process and thereby preserve residual insulin production leading to&#xD;
      fewer complications and better clinical outcomes.&#xD;
&#xD;
      The vast majority of genes that contribute to susceptibility to type 1 diabetes have been&#xD;
      found to encode proteins involved in immune regulation and function. In particular, several&#xD;
      susceptibility proteins are involved in the interleukin 2 (IL-2) pathway that regulates T&#xD;
      cell activation and tolerance to self antigens. Aldesleukin is a human recombinant IL-2&#xD;
      product produced by recombinant DNA technology using genetically engineered E. coli stain&#xD;
      containing an analog of the human interleukin-2 gene. There is substantial nonclinical,&#xD;
      preclinical and clinical data that ultra low dose IL-2 (aldesleukin) therapy can arrest the&#xD;
      autoimmune mediated destruction of pancreatic beta cells by induction of functional T&#xD;
      regulatory cells. However, prior to embarking on large proof of concept trials in type 1&#xD;
      diabetes it is essential that the optimum dose of IL-2 (aldesleukin) is determined. The&#xD;
      objective of this study is to establish in patients with type 1 diabetes the optimal dose of&#xD;
      IL-2 (aldesleukin) to administer in order to increase T regulatory cell response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is based upon the percentage of CD4+T regulatory (defined as CD3+CD4+CD25highCD127low) cells within the CD3+CD4+T cell gate following treatment with IL-2.</measure>
    <time_frame>From Day 0 to Day 60</time_frame>
    <description>Fluorescence-activated cell sorting assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T regulatory cell phenotype and stability</measure>
    <time_frame>From Day 0 to Day 60</time_frame>
    <description>Fluorescence-activated cell sorting assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T effector cell number and phenotype</measure>
    <time_frame>From Day 0 - Day 60</time_frame>
    <description>Fluorescence-activated cell sorting assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell subset proliferation and populations</measure>
    <time_frame>From Day 0 - Day 60</time_frame>
    <description>Fluorescence-activated cell sorting assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracellular T cell and natural killer(NK) cell signalling</measure>
    <time_frame>From Day 0 - Day 60</time_frame>
    <description>Fluorescence-activated cell sorting assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T regulatory cell function</measure>
    <time_frame>From Day 0 - Day 60</time_frame>
    <description>T suppression assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-2 pathway genotype</measure>
    <time_frame>From Day 0 - Day 60</time_frame>
    <description>DNA sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte Subsets</measure>
    <time_frame>From Day 0 to Day 60</time_frame>
    <description>Complete blood count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Cytokines</measure>
    <time_frame>From Day 0 to Day 60</time_frame>
    <description>Enzyme-linked immuno sorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycaemic control</measure>
    <time_frame>From Day 0 to Day 60</time_frame>
    <description>Self monitoring blood glucose readings, HbA1c, insulin usage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>From Day O to Day 60</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Type 1 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldesleukin (Proleukin)</intervention_name>
    <description>A single, subcutaneous dose will be given administered with the maximum dose allowed 1.5 X 106 IU/M2.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  18-50 years&#xD;
&#xD;
          -  Duration of diabetes less than 24 months from diagnosis&#xD;
&#xD;
          -  One positive autoantibody (anti-islet cell, anti-GAD, anti-IA2, anti-ZnT8)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to aldesleukin or any of the excipients&#xD;
&#xD;
          -  History of severe cardiac disease&#xD;
&#xD;
          -  History of malignancy within the past 5 years (with the exception of localized&#xD;
             carcinoma of the skin that had been resected for cure or cervical carcinoma in situ)&#xD;
&#xD;
          -  History or concurrent use of immunosuppressive agents or steroids&#xD;
&#xD;
          -  History of unstable diabetes with recurrent hypoglycaemia&#xD;
&#xD;
          -  Active autoimmune, hyper or hypothyroidism&#xD;
&#xD;
          -  Active clinical infection&#xD;
&#xD;
          -  Major pre-existing organ dysfunction or previous organ allograft&#xD;
&#xD;
          -  Females who are pregnant, lactating or intend to get pregnant during the study - Males&#xD;
             who intend to father a pregnancy during the study&#xD;
&#xD;
          -  Donation of more than 500 ml of blood within 2 months prior to aldesleukin&#xD;
             administration&#xD;
&#xD;
          -  Participation in a previous therapeutic clinical trial within 2 months prior to&#xD;
             aldesleukin administration&#xD;
&#xD;
          -  Abnormal ECG Abnormal full blood count, chronic renal failure (Stage 3,4,5) and/or&#xD;
             evidence impaired liver function&#xD;
&#xD;
          -  Positive Hepatitis B surface Antigen (HBsAg) or Hepatitis C serology or Human&#xD;
             Immunodeficiency Virus (HIV) test&#xD;
&#xD;
          -  Any medical history or clinically relevant abnormality that is deemed by the principal&#xD;
             investigator and/or medical monitor to make the patient ineligible for inclusion&#xD;
             because of a safety concern&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Waldron-Lynch</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wellcome Trust Clinical Research Facility, Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.facebook.com/ClinicalTrialsType1Diabetes</url>
    <description>DILT1D trial facebook page</description>
  </link>
  <link>
    <url>https://twitter.com/t1diabetestrial</url>
    <description>DILT1D trial Twitter update</description>
  </link>
  <reference>
    <citation>Waldron-Lynch F, Kareclas P, Irons K, Walker NM, Mander A, Wicker LS, Todd JA, Bond S. Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. BMJ Open. 2014 Jun 4;4(6):e005559. doi: 10.1136/bmjopen-2014-005559.</citation>
    <PMID>24898091</PMID>
  </reference>
  <results_reference>
    <citation>Heywood J, Evangelou M, Goymer D, Kennet J, Anselmiova K, Guy C, O'Brien C, Nutland S, Brown J, Walker NM, Todd JA, Waldron-Lynch F. Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D). Trials. 2015 Mar 11;16:86. doi: 10.1186/s13063-015-0583-7.</citation>
    <PMID>25881192</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>April 4, 2013</study_first_submitted>
  <study_first_submitted_qc>April 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2013</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Dr Frank Waldron-Lynch</investigator_full_name>
    <investigator_title>Academic Consultant Endocrinologist</investigator_title>
  </responsible_party>
  <keyword>Interleukin 2</keyword>
  <keyword>Type 1 diabetes</keyword>
  <keyword>T regulatory cells</keyword>
  <keyword>Adaptive trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 22, 2016</submitted>
    <returned>November 9, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

